Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer

Shiota, 2016, Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer, Int J Urol, 23, 360, 10.1111/iju.13091 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 368, 138, 10.1056/NEJMoa1209096 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Beer, 2014, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 371, 424, 10.1056/NEJMoa1405095 Tran, 2009, Development of a second-generation antiandrogen for treatment of advanced prostate cancer, Science, 324, 787, 10.1126/science.1168175 Scher, 2010, Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study, Lancet, 375, 1437, 10.1016/S0140-6736(10)60172-9 Ryan, 2010, Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy, J Clin Oncol, 28, 1481, 10.1200/JCO.2009.24.1281 Matsubara, 2014, Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer, Cancer Sci, 105, 1313, 10.1111/cas.12496 De Nunzio, 2020, Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies, Prostate Cancer Prostatic Dis, 23, 199, 10.1038/s41391-019-0182-x Yekedüz, 2021, Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?, Prostate Int, 9, 1, 10.1016/j.prnil.2020.03.002 American Society of Clinical Oncology, 1994, Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines, J Clin Oncol, 12, 2471, 10.1200/JCO.1994.12.11.2471 Shiota, 2020, Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide, Int J Urol, 27, 1109, 10.1111/iju.14366 Koura, 2021, Prognostic impact of prior local therapy in castration-resistant prostate cancer, Jpn J Clin Oncol, 51, 1142, 10.1093/jjco/hyab019 1997, Urologic Tumors Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Freedland, 2021, Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer, Curr Med Res Opin, 37, 635, 10.1080/03007995.2021.1888704 Vinh-Hung, 2020, Low-dose enzalutamide in late-elderly patients (≥ 75 years old) presenting with metastatic castration-resistant prostate cancer, Clin Genitourin Cancer, 18, e660, 10.1016/j.clgc.2020.03.019 Petrioli, 2015, Reduced dose of abiraterone acetate with concomitant low-dose prednisone in the treatment of ≥ 85 year-old patients with advanced castrate-resistant prostate cancer, Anticancer Res, 35, 3097 Szmulewitz, 2018, Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer, J Clin Oncol, 36, 1389, 10.1200/JCO.2017.76.4381 Patel, 2020, Low-dose abiraterone in metastatic prostate cancer: Is it practice changing? Facts and facets, JCO Glob Oncol, 6, 382, 10.1200/JGO.19.00341 Shiota, 2019, Association of missense polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or abiraterone, JAMA Netw Open, 2, 10.1001/jamanetworkopen.2019.0115 Shiota, 2021, The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer, Pharmacogenomics J, 21, 440, 10.1038/s41397-021-00220-0 Khalaf, 2019, Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial, Lancet Oncol, 20, 1730, 10.1016/S1470-2045(19)30688-6 Sternberg, 2020, Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, N Engl J Med, 382, 2197, 10.1056/NEJMoa2003892 Gibbons, 2015, Pharmacokinetic drug interaction studies with enzalutamide, Clin Pharmacokinet, 54, 1057, 10.1007/s40262-015-0283-1 Benoist, 2018, Drug-drug interaction potential in men treated with enzalutamide: Mind the gap, Br J Clin Pharmacol, 84, 122, 10.1111/bcp.13425 Bernard, 2015, Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin, Clin Pharmacol Drug Dev, 4, 63, 10.1002/cpdd.132 Monbaliu, 2016, In vitro and in vivo drug-drug interaction studies to assess the effect of abiraterone acetate, abiraterone, and metabolites of abiraterone on CYP2C8 activity, Drug Metab Dispos, 44, 1682, 10.1124/dmd.116.070672